The United Laboratories International Holdings Limited Applies for the Clinical Trial of its Class 1 Innovative New Drug UBT251 Injection
- Written by The Bulletin
HONG KONG SAR - Media OutReach - 20 June 2023 - On 15 June 2023, The United Bio-Technology (Hengqin) Co., Ltd. ("The United Bio-Technology"), a wholly-owned subsidiary of The United Laboratories International Holdings Limited ("TUL", the "Company" or the "Group"; Stock code: 3933), one of the leading pharmaceutical product manufacturers in the PRC, applied for the clinical trial of its self-developed class 1 innovative new drug UBT251 Injection on indications of adult type 2 diabetes, weight management and nonalcoholic fatty liver/nonalcoholic steatohepatitis ("NASH") and obtained the acceptance and payment notices by China National Medical Products Administration.
The Bulletin
